Page 761 - Small Animal Internal Medicine, 6th Edition

CHAPTER 45 Disorders of Micturition 733

POTENTIAL ADVERSE EFFECTS Restlessness, anxiety, tachycardia, hypertension Blood dyscrasias (rare when used at very neoplasia Alopecia, blood dyscrasia Sedation, hypotension Sedation, hypotension
VetBooks.ir low doses); mammary Continued

1-1.5 mg/kg PO q12-24h 0.5-1 mg/dog PO; give total dose daily for 3-5 days, then titrate down to lowest effective dose to maintain continence (once Begin loading dose of 2 mg/dog PO q24h; titrate down every 2 wk to lowest effect dose 0.01-0.05 mg/kg SC 1 mg/15 kg BW PO q8-12h (dog); 0.5 mg/cat

DOSAGE or twice/wk) q8-12h PO q12h

CLINICAL INDICATION(S) FOR USE To increase urethral closure pressure for urethral sphincter mechanism incompetence (USMI) To increase urethral closure pressure for USMI To increase urethral closure pressure for USMI To decrease urethral closure pressure for functional urethral outflow tract obstruction To decrease urethral closure pressure for functional urethral outflow tract obstruction

Commonly Used Drugs for Micturition Disorders in Small Animal Patients
MECHANISM OF ACTION Indirectly stimulates α- and β-receptors by causing release of norepinephrine (NE) May sensitize α 1 - adrenergic receptors to NE May sensitize α 1 - adrenergic receptors to NE Varying degrees of antispasmodic and α-adrenergic blocking capabilities Inhibits α 1 -receptors

CLASS α 1 -agonist Synthetic estrogen Natural estrogen Phenothiazine derivative α-adrenergic antagonist

TABLE 45.1 DRUG (TRADE NAME) Phenylpropanolamine (PPA) Diethylstilbestrol (DES) Estriol (Incurin) Acepromazine (PromAce) Prazosin (Minipress)